{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004118","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.582588+00:00","generated_at":"2026-05-18T18:50:07.730134+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aptose signs up to $8.5M uncommitted loan from Hanmi for Tuspetinib AML clinical development","bullets":["Loan agreement with Hanmi Pharmaceutical for up to $8.5M uncommitted non-revolving facility.","Funds to be used for Tuspetinib triple drug therapy for newly diagnosed AML, accounts payable, and TUS-related corporate purposes.","Advances up to $2.5M each, available until Dec 31, 2025; maturity date Aug 31, 2028.","Loan bears 6% interest per annum; secured by first ranking security on all personal property of Aptose and subsidiary guarantees.","Previous 2024 facility agreement also exists; new loan is separate."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004118","json":"https://secwatch.observer/filing/0001171843-25-004118.json","markdown":"https://secwatch.observer/filing/0001171843-25-004118.md","text":"https://secwatch.observer/filing/0001171843-25-004118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325004118/0001171843-25-004118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325004118/f8k_062625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T18:50:07.730134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e00e20220a39ccca86ae3756cacd70e5f0c140c","claim":"Aptose Biosciences Inc. incurred credit facility of up to US$8.5 million with Hanmi Pharmaceutical Co. Ltd. at six percent (6%) per annum maturing August 31, 2028.","evidence_excerpt":"On June 20, 2025, Aptose Biosciences Inc., as borrower (the “Company”), announced that it had entered into a loan agreement (the “Loan Agreement”) with Hanmi Pharmaceutical Co. Ltd., as lender (“Hanmi”). The Loan Agreement is an uncommitted facility for up to US$8.5 million (the “Facility”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184325004118/0001171843-25-004118-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to US$8.5 million"},{"label":"Counterparty","value":"Hanmi Pharmaceutical Co. Ltd."},{"label":"Rate","value":"six percent (6%) per annum"},{"label":"Maturity","value":"August 31, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}